In 2018, Lugano et al. confirmed CD93 upregulation in glioblastoma blood vessels compared to normal brain vessels and identified a CD93/MMRN2/β1 integrin/fibronectin signaling axis, revealing a new mechanism for integrin activity regulation in cancer angiogenesis. This evidence concerns the gene CD93 and glioblastoma.